Patients with uveitis exhibited lower risk for TB with adalimumab therapy, though the risk was not completely eliminated.

PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving ...

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need for corticosteroid use in patients with noninfectious uveitis, according ...

Dr Oskouei explains the indications for adalimumab and the impact of their extrapolation, as well as differences among adalimumab products. Sonia T. Oskouei, PharmD, BCMAS, DPLA: All biosimilars ...

Review the side-effects of Adalimumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

plaque psoriasis The efficacy, safety, pharmacokinetics, and immunogenicity of adalimumab combined with MTX compared with that adalimumab in patients with chronic plaque psoriasis is evaluated. Adding ...

Please provide your email address to receive an email when new articles are posted on . In a phase 3, randomized, double-blind study, researchers compared the safety and efficacy of biosimilar BI ...

Background Adalimumab is an effective first-line biologic therapy used to treat children and young people (CYP) with juvenile ...

Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

Please provide your email address to receive an email when new articles are posted on . IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is ...

Yuflyma (adalimumab-aaty) and its unbranded version may now be prescribed for HS in patients 12 years and older and for UV in children 2 years and older. The Food and Drug Administration (FDA) has ...

PALO ALTO, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company today announced that ...